• Using “High Potentials” to Combat Life-Threatening Diseases

    New Technologies for the Production of Highly Potent Active Ingredients

    show caption

    Emergency preparedness: Wearing a protective suit with respirator, Adam Mikolasch makes preparations to take a sample.

They are the “high potentials” of the medical world. Highly potent active ingredients are substances that take full effect even in extremely small doses. Special safety measures are therefore required for their manufacture. Using advanced technologies, Bayer researchers in Chemical Development have made their production areas safer and significantly more efficient – from synthesis in the laboratory through to multi-kilogram production.

Story check

  • Challenge
    The demand for high potency active ingredients in medicine is growing, but they present major challenges to manufacturers.
  • Solution
    Bayer has built a technically sophisticated facility to manufacture high potency active ingredients, both for clinical trials and for the market.
  • Benefits
    Handling the active ingredients in a closed system reduces contamination to a minimum, which in turn significantly shortens the cleaning times in the technical laboratories.

The purity law: Adam Mikolasch uses a continuous tube system that transports the highly potent active ingredient through a dust-free and ­hermetically sealed environment to final packaging.

A production plant for a high potency active ingredient must be

100 times

more airtight than one for a conventional active substance.

Highly potent active ingredients (HPAI) are highly effective and often highly selective substances that have been developed to treat life-threatening disea­ses. The therapeutic doses of such active ingredients are often only one-hundredth of the dosage of conventional headache pills. “Improved optimization processes and state-of-the-art screening techno­logies enable us today to find and deve­lop drug candidates that are significantly more effective and selective and thus take effect already at a low dose,” explains Dr. Timo Flessner, Head of Chemical Development at Bayer in Wuppertal. Medical researchers are therefore increasingly turning their attention to HPAIs for cancer treatments but also some cardiovascular drugs, and this segment of the drug market is growing continuously. “Highly potent active substances make up an increasing share of the chemical compounds in Bayer’s pharmaceuticals pipeline today,” says Flessner. A special technical infrastructure is however mandatory for the manufacture and handling of HPAIs. “It is precisely because they are so highly potent that we were forced to adapt our production technologies,” adds Mathias Berwe, Head of HPAI Production at Bayer in Wuppertal. The reason is that even micro amounts in the air can negatively impact the health of employees handling these substances on a daily basis. “We have to be particularly diligent about protecting our team against these highly potent active substances throughout all production and handling steps,” adds Dr. Ralf Wischnat, Head of Scale-Up & Processing in Chemical Development at Bayer.

One milestone in the series of associated investments is the HPAI technical lab in Wuppertal. It encompasses both laboratories that produce only a few grams of the active ingredients, and facilities for producing several kilograms. “The new equipment enables us to handle the active ingredients in a closed system.

Emergency preparedness: Mathias Berwe and Dr. Ralf Wischnat (left to right) inspect the plant at the technical lab in Wuppertal prior to manufacturing a new active ingredient.

Production Challenges: HPAIs Need Special Safety Measures

That reduces contamination to a minimum, which in turn significantly shortens the cleaning times in the technical laboratories,” says Wischnat. “And especially in the early phase of development, any time we can save is valuable.”

The global market for HPAIs is forecast to increase by roughly

10 percent

by 2018, to a market value of EUR 19 billion.

Strict industrial hygiene standards are applied right from the start of development of any chemical process. “Just one milligram of a highly potent active ingredient can contaminate 1,000 cubic meters of air,” reports Berwe. The HPAIs are therefore produced inside a glove box. In this hermetically sealed space, employees use integrated gloves to manipulate the substances. The pressure inside is below the room pressure, meaning that even the minutest particles cannot escape.

“If fairly large quantities of an active substance are required, we switch over to a pilot plant. Here, we manufacture product by the kilogram based on advanced production processes and ensure substance supply all the way through to drug approval,” explains Wischnat. Bayer specialists from Research, Development and Production work together closely on such projects: combined with Process Engineering colleagues, the chemical process development experts scale up the synthesis process, making sure that they find the optimum input quantities and conditions such as pressure, temperature and reaction time. The inputs are fed in a dust-free and hermetically sealed environment to the plant, where chemical conversion and processing take place. The wet, target product ends up in a drier, which converts it into a crystalline powder. “After a drug is approved, we then transfer the process to the final production plant with the help of our colleagues at Product Supply,” says Wischnat.

Active ingredient production in a hermetic system

To remove the pure drug substance safely, a continuous tube system is used which was developed in partnership with an external company. It transports the active ingredient directly into the final packaging unit without any contamination whatsoever. “The investment now allows us to support all steps of the process, from laboratory processing to market ­intro­duction of the HPAIs. For certain active ingredients we also use Chemical Development’s pilot plant to ensure a long-term supply of products for the market,” summarizes Flessner.